Pyrotinib Boosts Survival in HER2+ Metastatic Breast Cancer

Patients treated with pyrotinib plus capecitabine survived longer than those treated with lapatinib plus capecitabine in the PHOEBE trial.
Medscape Medical News

source https://www.medscape.com/viewarticle/965253?src=rss

Comments

Popular posts from this blog

New AAFP practice guideline sets blood pressure targets for adults with hypertension